Quick Take
- Narration: Marina Gerner reads her own work with the focused authority of a researcher who has spent years in this material, her academic precision never tips into dryness, and the interviews she weaves in give the performance genuine variety.
- Themes: Women’s health innovation, femtech investment gap, systemic healthcare inequity
- Mood: Energized and investigative, with a persistent low-grade outrage that feels entirely earned
- Verdict: If you want to understand why the femtech sector is both exploding with possibility and still fighting for scraps of venture capital, this is the clearest account available in audio form.
I finished the last hour of this one on a Sunday evening, sitting at my kitchen table after a week that had included two separate conversations with friends about medical issues their doctors had dismissed for years. The timing felt almost uncomfortably apt. Marina Gerner opens with a statistic that should be enraging but has somehow become background noise: women make over 80% of healthcare decisions in the US, yet only 4% of medical research and development is focused on women’s health issues. She doesn’t let that number float by as an abstract injustice. She builds everything that follows on top of it, methodically and with real anger kept elegantly in check.
This is investigative journalism in audiobook form, and it works precisely because Gerner is both the author and the narrator. She conducted interviews with 100 entrepreneurs across 15 countries, and her voice carries the ownership of that research. When she describes a vaginal dilator designed to reduce tearing during childbirth, or an in-home fertility system that reads saliva, you hear the specific curiosity of someone who has sat across from these founders and watched their products work. That intimacy doesn’t come through in a hired voice reading someone else’s reportage.
The 4% Problem and What Comes After It
Gerner is at her sharpest when she traces how the healthcare gap wasn’t created by ignorance but by institutional indifference compounded over decades. Female pain has been normalized, she argues, not because medicine lacks the tools to address it but because the question was never asked seriously enough to generate funding. The examples she assembles, EKG bras that can predict heart attacks, apps providing safe access to medical abortions, pelvic floor devices for menopause, aren’t speculative futures. They exist. They are in development or already on the market. The gap isn’t technological. It’s financial and cultural.
The boardroom sections are some of the most useful parts of the book, and also the most sobering. Only 2.1% of venture capital dollars go toward companies founded by women. Gerner doesn’t just report this figure; she interrogates why it persists, drawing on conversations with investors, founders, and executives to build a picture of how bias operates not as overt hostility but as the quieter habit of funding what feels familiar. For listeners who work in or adjacent to investment and startups, this section will feel pointed in ways the broader healthcare framing doesn’t quite capture.
A Global Scope That Sometimes Rushes
The 15-country reach is a genuine strength, and it’s one of the reasons the book feels different from American-only takes on the femtech conversation. Gerner brings in perspectives from founders working in regulatory environments very different from the FDA’s, and the contrast illuminates how much of what gets called a universal women’s health problem is actually a specific set of policy choices. That said, the breadth occasionally works against depth. Some of the 100 entrepreneurs she interviewed appear only briefly, as quick examples rather than full case studies. A few of the technologies mentioned deserve more time than they get. At 10 hours and 43 minutes, there’s room for this material to breathe, and there are moments where the pace feels like it’s checking boxes rather than fully unpacking what it’s found.
Reviewers have described the book as smart, timely, and deeply researched, and that’s accurate. One reader noted that Gerner combines storytelling with sharp analysis to argue that investing in women’s health is not only moral but economically rational. That dual framing, the ethical and the financial case made simultaneously, is one of the more deft rhetorical moves in the book, and it’s one that likely broadens the intended audience beyond readers who are already sympathetic to the premise.
Who Should Listen and Who Should Think Twice
This audiobook is well-suited for women working in healthcare, investment, or entrepreneurship who want a mapped view of the femtech landscape rather than a personal empowerment narrative. It also works for anyone who has ever been told their pain was normal when they suspected it wasn’t, and who wants evidence that the systems producing that dismissal are being challenged. Listeners looking for deep policy analysis or peer-reviewed citation will find the journalistic approach somewhat light; this is a book of interviews and reported narrative, not an academic text. And if you come to it already fluent in femtech funding debates, some of the early groundwork may feel familiar. But as an introduction to the scope and ambition of the sector, told by someone who spent years inside it, there’s very little that does this job better.
Frequently Asked Questions
Does Marina Gerner’s academic background as a PhD come through in the narration, and does it help or hinder the listening experience?
It helps. Gerner’s academic precision keeps the reporting tight without making the narration feel stiff. She moves between interview material and her own analysis fluidly, and the effect is closer to a well-produced documentary than a lecture.
Does the book cover LGBTQIA health needs specifically, or is it focused primarily on cisgender women’s issues?
Gerner explicitly includes healthcare apps tailored to LGBTQIA people among the innovations she profiles, though the coverage is not exhaustive. The book acknowledges the limitations of a binary health framework more directly than most femtech writing does.
Is the 10-hour runtime justified by the material, or does it feel padded?
The runtime is mostly earned. The 100-entrepreneur scope means there’s a lot of ground to cover, and Gerner uses the time to build a cumulative argument rather than repeat herself. The boardroom and investment sections toward the middle are the densest, and worth the full attention they require.
How dated is the technology content? Some of these products may have changed since publication.
Some of the specific products and startups mentioned will have evolved since Gerner researched the book. The structural arguments about investment gaps and regulatory barriers remain accurate, but listeners interested in specific companies should verify current status independently.
